1IFH
 
 | |
7KMK
 | | cryo-EM structure of SARS-CoV-2 spike in complex with Fab 15033-7, two RBDs bound | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Fab 15033-7 heavy chain, ... | | Authors: | Li, Z, Rini, J.M. | | Deposit date: | 2020-11-03 | | Release date: | 2021-02-10 | | Last modified: | 2021-08-25 | | Method: | ELECTRON MICROSCOPY (4.2 Å) | | Cite: | Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations.
J.Mol.Biol., 433, 2021
|
|
7KLG
 | | SARS-CoV-2 RBD in complex with Fab 15033 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Fab 15033 heavy chain, Fab 15033 light chain, ... | | Authors: | Li, Z, Rini, J.M. | | Deposit date: | 2020-10-30 | | Release date: | 2021-02-10 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (3.2 Å) | | Cite: | Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations.
J.Mol.Biol., 433, 2021
|
|
7KML
 | | cryo-EM structure of SARS-CoV-2 spike in complex with Fab 15033-7, three RBDs bound | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Fab 15033-7 heavy chain, ... | | Authors: | Li, Z, Rini, J.M. | | Deposit date: | 2020-11-03 | | Release date: | 2021-02-10 | | Last modified: | 2021-08-25 | | Method: | ELECTRON MICROSCOPY (3.8 Å) | | Cite: | Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations.
J.Mol.Biol., 433, 2021
|
|
7KLH
 | | SARS-CoV-2 RBD in complex with Fab 15033-7 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Fab 15033-7 heavy chain, Fab 15033-7 light chain, ... | | Authors: | Li, Z, Rini, J.M. | | Deposit date: | 2020-10-30 | | Release date: | 2021-02-10 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (3 Å) | | Cite: | Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations.
J.Mol.Biol., 433, 2021
|
|
1FRG
 | |
1GGB
 | |
1GGC
 | |
1QSJ
 | | N-TERMINALLY TRUNCATED C3DG FRAGMENT | | Descriptor: | COMPLEMENT C3 PRECURSOR | | Authors: | Zanotti, G, Bassetto, A, Battistutta, R, Stoppini, M, Folli, C, Berni, R. | | Deposit date: | 1999-06-22 | | Release date: | 2000-07-31 | | Last modified: | 2021-11-03 | | Method: | X-RAY DIFFRACTION (1.9 Å) | | Cite: | Structure at 1.44 A resolution of an N-terminally truncated form of the rat serum complement C3d fragment.
Biochim.Biophys.Acta, 1478, 2000
|
|
1QQF
 | | N-TERMINALLY TRUNCATED C3D,G FRAGMENT OF THE COMPLEMENT SYSTEM | | Descriptor: | PROTEIN (COMPLEMENT C3DG) | | Authors: | Zanotti, G, Bassetto, A, Battistutta, R, Stoppini, M, Berni, R. | | Deposit date: | 1999-06-04 | | Release date: | 2000-07-31 | | Last modified: | 2015-01-21 | | Method: | X-RAY DIFFRACTION (1.45 Å) | | Cite: | Structure at 1.44 A resolution of an N-terminally truncated form of the rat serum complement C3d fragment.
Biochim.Biophys.Acta, 1478, 2000
|
|
6Q2W
 | | Crystal structure of human ROR gamma LBD in complex with a quinoline sulfonamide inverse agonist | | Descriptor: | (2~{S})-1-[2,4-bis(chloranyl)-3-[[4-imidazol-1-yl-2-(trifluoromethyl)quinolin-8-yl]oxymethyl]phenyl]sulfonyl-~{N}-methyl-pyrrolidine-2-carboxamide, Nuclear receptor ROR-gamma | | Authors: | Ciesielski, F, Amaudrut, J, Argiriadi, M.A, Barth, M, Breinlinger, E.C, Calderwood, D.J, Cusack, K.P, Kort, M.E, Montalbetti, C, Potin, D, Poupardin, O, Spitzer, L. | | Deposit date: | 2018-12-03 | | Release date: | 2019-05-29 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (1.99 Å) | | Cite: | Discovery of novel quinoline sulphonamide derivatives as potent, selective and orally active ROR gamma inverse agonists.
Bioorg.Med.Chem.Lett., 29, 2019
|
|
6HHO
 | | Crystal structure of RIP1 kinase in complex with GSK547 | | Descriptor: | 6-[4-[(5~{S})-5-[3,5-bis(fluoranyl)phenyl]pyrazolidin-1-yl]carbonylpiperidin-1-yl]pyrimidine-4-carbonitrile, Receptor-interacting serine/threonine-protein kinase 1 | | Authors: | Thorpe, J.H, Harris, P.A. | | Deposit date: | 2018-08-28 | | Release date: | 2018-12-12 | | Last modified: | 2024-01-17 | | Method: | X-RAY DIFFRACTION (3.49 Å) | | Cite: | RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer.
Cancer Cell, 34, 2018
|
|
6RLN
 | | Crystal structure of RIP1 kinase in complex with GSK3145095 | | Descriptor: | Receptor-interacting serine/threonine-protein kinase 1, ~{N}-[(3~{S})-7,9-bis(fluoranyl)-2-oxidanylidene-1,3,4,5-tetrahydro-1-benzazepin-3-yl]-3-(phenylmethyl)-1~{H}-1,2,4-triazole-5-carboxamide | | Authors: | Thorpe, J.H, Harris, P.A. | | Deposit date: | 2019-05-02 | | Release date: | 2019-07-03 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (2.87 Å) | | Cite: | Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer.
Acs Med.Chem.Lett., 10, 2019
|
|
6ENQ
 | | Structure of human PPAR gamma LBD in complex with Lanifibranor (IVA337) | | Descriptor: | 4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloro-indol-2-yl]butanoic acid, Peroxisome proliferator-activated receptor gamma | | Authors: | Boubia, B, Poupardin, O, Barth, M, Amaudrut, J, Broqua, P, Tallandier, M, Zeyer, D. | | Deposit date: | 2017-10-06 | | Release date: | 2018-03-14 | | Last modified: | 2024-01-17 | | Method: | X-RAY DIFFRACTION (2.2 Å) | | Cite: | Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) alpha / gamma / delta Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.
J. Med. Chem., 61, 2018
|
|
